Safwaan Adam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Safwaan Adam has a total of 214 co-authors. Here are the top co-authors by number of shared publications:
- Akheel A. Syed
Department of Diabetes, Endocrinology and Obesity Medicine, Salford Care Organisation, Northern Care Alliance NHS Foundation Trust, Greater Manchester, United Kingdom
21 shared publications - Handrean Soran
Division of Cardiovascular Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester M13 9PT, UK
21 shared publications Handrean Soran
Cardiovascular Research Group, The University of Manchester, Manchester, UK
16 shared publicationsYifen Liu
Faculty of Biology, Medicine and Health, University of Manchester , Manchester M13 9WU , United Kingdom
13 shared publicationsJan Hoong Ho
Department of Endocrinology, The Christie Hospital NHS Foundation Trust, Manchester, UK
11 shared publications- Rachelle Donn
The School of Medicine and Manchester Academic Health Sciences Centre, Manchester University, Manchester M13 9PL, UK
10 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Diagnostic accuracy study of morning salivary cortisone for screening adrenal insufficiency in a real-world cohort
Context: Morning serum cortisol is used to screen for adrenal insufficiency, but requires venepuncture, early morning clinic attendance, and may be affected by altered corticosteroid-binding globulin (CBG) levels. Salivary cortisone is a noninvasive, home-based alternative. Objective: To assess the diagnostic accuracy of morning salivary cortisone for screening adrenal insufficiency and establish clinically relevant thresholds. Design: Retrospective cross-sectional diagnostic accuracy study (2017 to 2024). Setting: Single tertiary oncology and endocrinology center in the United Kingdom. Participants: Consecutive patients undergoing adrenocorticotropin hormone (ACTH) stimulation test for suspected adrenal insufficiency. Intervention: Salivary sampling for cortisone and cortisol. Main Outcome Measures: Sensitivity and specificity of baseline salivary cortisone. Results: A total of 517 ACTH stimulation tests in 449 participants were included; adrenal insufficiency was confirmed in 104 tests (20.1%). Baseline salivary cortisone accurately predicted adrenal insufficiency (area under the receiver operating characteristic curve [AUC] 0.93, 95% CI [0.91-0.95]), similar to serum cortisol (0.93, 0.90-0.95; P = .67) and superior to salivary cortisol (0.87, 0.82-0.91; P = .00063). A baseline salivary cortisone rule-out threshold ≥703 ng/dL (19.5 nmol/L) (sensitivity 0.97 [95% CI 0.92-0.99]; specificity 0.59 [0.54-0.63]) and a rule-in threshold <180 ng/dL (5.0 nmol/L) (sensitivity 0.58 [0.48-0.67]; specificity 0.97 [0.95-0.98]) provided the highest net benefit. An intermediate threshold <389 ng/dL (10.8 nmol/L) (sensitivity 0.83 [0.74-0.89]; specificity 0.87 [0.83-0.90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory testing. Conclusion: Baseline morning salivary cortisone performs at least as well as serum cortisol for adrenal insufficiency screening.
- 29 September 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessDiagnostic accuracy study of morning salivary cortisone for screening adrenal insufficiency in a real-world cohort
Context: Morning serum cortisol is used to screen for adrenal insufficiency, but requires venepuncture, early morning clinic attendance, and may be affected by altered corticosteroid-binding globulin (CBG) levels. Salivary cortisone is a noninvasive, home-based alternative. Objective: To assess the diagnostic accuracy of morning salivary cortisone for screening adrenal insufficiency and establish clinically relevant thresholds. Design: Retrospective cross-sectional diagnostic accuracy study (2017 to 2024). Setting: Single tertiary oncology and endocrinology center in the United Kingdom. Participants: Consecutive patients undergoing adrenocorticotropin hormone (ACTH) stimulation test for suspected adrenal insufficiency. Intervention: Salivary sampling for cortisone and cortisol. Main Outcome Measures: Sensitivity and specificity of baseline salivary cortisone. Results: A total of 517 ACTH stimulation tests in 449 participants were included; adrenal insufficiency was confirmed in 104 tests (20.1%). Baseline salivary cortisone accurately predicted adrenal insufficiency (area under the receiver operating characteristic curve [AUC] 0.93, 95% CI [0.91-0.95]), similar to serum cortisol (0.93, 0.90-0.95; P = .67) and superior to salivary cortisol (0.87, 0.82-0.91; P = .00063). A baseline salivary cortisone rule-out threshold ≥703 ng/dL (19.5 nmol/L) (sensitivity 0.97 [95% CI 0.92-0.99]; specificity 0.59 [0.54-0.63]) and a rule-in threshold <180 ng/dL (5.0 nmol/L) (sensitivity 0.58 [0.48-0.67]; specificity 0.97 [0.95-0.98]) provided the highest net benefit. An intermediate threshold <389 ng/dL (10.8 nmol/L) (sensitivity 0.83 [0.74-0.89]; specificity 0.87 [0.83-0.90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory testing. Conclusion: Baseline morning salivary cortisone performs at least as well as serum cortisol for adrenal insufficiency screening.
- Open Access
- 27 March 2026
- Published by Elsevier in SSRN Electronic Journal
Evaluating the Diagnostic Performance of Morning Salivary Cortisone in the Screening of Adrenal Insufficiency in a Real-World Cohort
Introduction: Morning serum cortisol (SerF) is used to screen for adrenal insufficiency (AI), but requires venepuncture, clinic attendance, and could be affected by conditions alternating corticosteroid-binding globulin (CBG) levels. Salivary cortisone (SalE) has emerged as a non-invasive alternative. We aimed to assess the diagnostic accuracy of morning SalE and define clinically relevant thresholds for AI screening. Methods: This retrospective study was conducted at a UK tertiary oncology and endocrinology centre. We analysed consecutive short Synacthen test (SST; reference standard) with paired morning SerF, salivary cortisol (SalF), and SalE measurements in adults. Receiver operating characteristic analysis was used to derive thresholds, and decision curve analysis assessed net benefit across threshold probabilities of 0·10-0·30. Results: 517 SSTs in 449 participants were included; 104 SSTs (20·1%) showed AI. Baseline SalE was a strong predictor of AI (area under the receiver operating characteristic curve [AUC] 0·93, 95% CI 0·91–0·95]), comparable to SerF (0·93, 0·90–0·95; p = 0·67) and superior to SalF (0·87, 0·82–0·91; p = 0·00063). A baseline SalE rule-out threshold ≥ 19·5 nmol/L (sensitivity 0·97 [95% CI 0·92–0·99]; specificity 0·59 [0·54–0·63]) and a rule-in threshold < 5·0 nmol/L (sensitivity 0·58 [0·48–0·67]; specificity 0·97 [0·95–0·98]) provided the highest net benefit. An intermediate threshold < 10·8 nmol/L (sensitivity 0·83 [0·74–0·89]; specificity 0·87 [0·83–0·90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory SST. Conclusion: In conclusion, baseline morning SalE perform at least as well as conventional SerF approach for AI screening and could reduce unnecessary SSTs.
- 27 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessEvaluating the Diagnostic Performance of Morning Salivary Cortisone in the Screening of Adrenal Insufficiency in a Real-World Cohort
Introduction: Morning serum cortisol (SerF) is used to screen for adrenal insufficiency (AI), but requires venepuncture, clinic attendance, and could be affected by conditions alternating corticosteroid-binding globulin (CBG) levels. Salivary cortisone (SalE) has emerged as a non-invasive alternative. We aimed to assess the diagnostic accuracy of morning SalE and define clinically relevant thresholds for AI screening. Methods: This retrospective study was conducted at a UK tertiary oncology and endocrinology centre. We analysed consecutive short Synacthen test (SST; reference standard) with paired morning SerF, salivary cortisol (SalF), and SalE measurements in adults. Receiver operating characteristic analysis was used to derive thresholds, and decision curve analysis assessed net benefit across threshold probabilities of 0·10-0·30. Results: 517 SSTs in 449 participants were included; 104 SSTs (20·1%) showed AI. Baseline SalE was a strong predictor of AI (area under the receiver operating characteristic curve [AUC] 0·93, 95% CI 0·91–0·95]), comparable to SerF (0·93, 0·90–0·95; p = 0·67) and superior to SalF (0·87, 0·82–0·91; p = 0·00063). A baseline SalE rule-out threshold ≥ 19·5 nmol/L (sensitivity 0·97 [95% CI 0·92–0·99]; specificity 0·59 [0·54–0·63]) and a rule-in threshold < 5·0 nmol/L (sensitivity 0·58 [0·48–0·67]; specificity 0·97 [0·95–0·98]) provided the highest net benefit. An intermediate threshold < 10·8 nmol/L (sensitivity 0·83 [0·74–0·89]; specificity 0·87 [0·83–0·90]) identified patients for whom glucocorticoid cover should be considered while awaiting confirmatory SST. Conclusion: In conclusion, baseline morning SalE perform at least as well as conventional SerF approach for AI screening and could reduce unnecessary SSTs.
- Open Access
- 15 July 2025
- Published by Elsevier in The Breast
- Vol. 83, 104536
Acute presentations in neoadjuvant chemotherapy/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data
- 15 July 2025
- Published by Elsevier in The Breast
- Vol. 83, 104536
Open AccessAcute presentations in neoadjuvant chemotherapy/immune checkpoint inhibition for triple negative breast cancer: experiences and impact from real-world data
- Open Access
- 19 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 362
The Relationship Between Obesity and Cancer: Epidemiology, Pathophysiology, and the Effect of Obesity Treatment on Cancer
There is growing evidence relating to the risk of cancer in people with obesity. Obesity is already established as one of the strongest predisposing factors to cancer, and ‘obesity-related’ cancers have been defined in previous studies. In this review article, we examine the epidemiological relationship and describe the potential pathophysiological mechanisms that underpin the association between obesity and cancer. These include hormonal and growth factors that are in abundance in persons living with obesity and thereby increase cancer risk. Additionally, the increased disposition towards chronic inflammation in obesity also confers cancer risk. We also examine the impact of obesity on cancer treatment outcomes, focusing on surgery, chemotherapy, and immunotherapy. Conversely, we underline the impact of weight loss on cancer risk by examining different weight loss strategies.
- 19 June 2025
- Published by MDPI AG in Current Oncology
- Vol. 32 (6) , 362
Open AccessThe Relationship Between Obesity and Cancer: Epidemiology, Pathophysiology, and the Effect of Obesity Treatment on Cancer
There is growing evidence relating to the risk of cancer in people with obesity. Obesity is already established as one of the strongest predisposing factors to cancer, and ‘obesity-related’ cancers have been defined in previous studies. In this review article, we examine the epidemiological relationship and describe the potential pathophysiological mechanisms that underpin the association between obesity and cancer. These include hormonal and growth factors that are in abundance in persons living with obesity and thereby increase cancer risk. Additionally, the increased disposition towards chronic inflammation in obesity also confers cancer risk. We also examine the impact of obesity on cancer treatment outcomes, focusing on surgery, chemotherapy, and immunotherapy. Conversely, we underline the impact of weight loss on cancer risk by examining different weight loss strategies.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2400312
Development of a Machine Learning Algorithm to Predict Abnormalities in Serum Phosphate in a Large Oncology Cohort
PURPOSE: Serum phosphate is commonly measured in oncology patients because of the relationship between oncologic conditions and treatments with abnormal phosphate. All patients attending our institution, a large specialist oncology center, have a standardized order set (SOS) measured. This consists of 15 biochemical tests, including serum phosphate. Our aim was to understand if abnormalities in serum phosphate could be predicted, using a machine learning algorithm (MLA) by other interrelated variables in the SOS. METHODS: We trained an XGBoost MLA implemented in Python to predict occurrence of abnormal phosphate (1.78 mmol/L) from other results in the SOS. To train and test this algorithm, we used 481,150 test results for 45,174 patients on blood tests between January 2019 and December 2021, with 5,897 abnormal results. RESULTS: This model was trained and tested on a 70%/30% split (train/test result cohort), achieving an area under the receiver operator curve on the test set of 0.866 (95% CI, 0.857 to 0.875). Assigning a threshold for predictions so the model achieves a sensitivity of 0.924 and a specificity of 0.530 and only performing a phosphate test for results above this threshold, the number of phosphate tests would be reduced from 142,647 to 67,873 in this test set, capturing 1,586 of the total 1,716 abnormal results with a small risk (<0.1%) of missing an abnormal result. The model was further validated on a separate validation cohort between January 2022 and December 2023, achieving similar levels of performance. CONCLUSION: A MLA to optimize testing of phosphate has been developed with high sensitivity. Its application in routine care might result in cost-savings and health care efficiencies. The methodology used to develop our MLA model can be applied to other settings where interrelated variables are measured in SOS.
- 1 April 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Clinical Cancer Informatics
- Vol. 9 (9) , e2400312
Development of a Machine Learning Algorithm to Predict Abnormalities in Serum Phosphate in a Large Oncology Cohort
PURPOSE: Serum phosphate is commonly measured in oncology patients because of the relationship between oncologic conditions and treatments with abnormal phosphate. All patients attending our institution, a large specialist oncology center, have a standardized order set (SOS) measured. This consists of 15 biochemical tests, including serum phosphate. Our aim was to understand if abnormalities in serum phosphate could be predicted, using a machine learning algorithm (MLA) by other interrelated variables in the SOS. METHODS: We trained an XGBoost MLA implemented in Python to predict occurrence of abnormal phosphate (1.78 mmol/L) from other results in the SOS. To train and test this algorithm, we used 481,150 test results for 45,174 patients on blood tests between January 2019 and December 2021, with 5,897 abnormal results. RESULTS: This model was trained and tested on a 70%/30% split (train/test result cohort), achieving an area under the receiver operator curve on the test set of 0.866 (95% CI, 0.857 to 0.875). Assigning a threshold for predictions so the model achieves a sensitivity of 0.924 and a specificity of 0.530 and only performing a phosphate test for results above this threshold, the number of phosphate tests would be reduced from 142,647 to 67,873 in this test set, capturing 1,586 of the total 1,716 abnormal results with a small risk (<0.1%) of missing an abnormal result. The model was further validated on a separate validation cohort between January 2022 and December 2023, achieving similar levels of performance. CONCLUSION: A MLA to optimize testing of phosphate has been developed with high sensitivity. Its application in routine care might result in cost-savings and health care efficiencies. The methodology used to develop our MLA model can be applied to other settings where interrelated variables are measured in SOS.
- Open Access
- 21 February 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 113949
Thyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study
- 21 February 2024
- Published by Elsevier in European Journal of Cancer
- Vol. 202, 113949
Open AccessThyroid dysfunction after immune checkpoint inhibitors in a single-centre UK pan-cancer cohort: A retrospective study
- 26 August 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (10) , 3460-3462
Response to Letter to the Editor Concerning: Adam S. et al. Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study
- 26 August 2022
- Published by Springer Nature in Obesity Surgery
- Vol. 32 (10) , 3460-3462
Response to Letter to the Editor Concerning: Adam S. et al. Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study
- 27 May 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (8) , 2182-2194
Bariatric Surgery-induced High-density Lipoprotein Functionality Enhancement Is Associated With Reduced Inflammation
Background Emerging evidence suggests an association between impaired high-density lipoprotein (HDL) functionality and cardiovascular disease (CVD). HDL is essential for reverse cholesterol transport (RCT) and reduces inflammation and oxidative stress principally via paraoxonase-1 (PON1). RCT depends on HDL’s capacity to accept cholesterol (cholesterol efflux capacity [CEC]) and active transport through ATP-binding cassette (ABC) A1, G1, and scavenger receptor-B1 (SR-B1). We have studied the impact of Roux-en-Y gastric bypass (RYGB) in morbidly obese subjects on RCT and HDL functionality. Methods Biomarkers associated with increased CVD risk including tumour necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hsCRP), myeloperoxidase mass (MPO), PON1 activity, and CEC in vitro were measured in 44 patients before and 6 and 12 months after RYGB. Overweight but otherwise healthy (mean body mass index [BMI] 28 kg/m2) subjects acted as controls. Twelve participants also underwent gluteal subcutaneous adipose tissue biopsies before and 6 months after RYGB for targeted gene expression (ABCA1, ABCG1, SR-B1, TNF-α) and histological analysis (adipocyte size, macrophage density, TNF-α immunostaining). Results Significant (P < 0.05) improvements in BMI, HDL-cholesterol, hsCRP, TNF-α, MPO mass, PON1 activity, and CEC in vitro were observed after RYGB. ABCG1 (fold-change, 2.24; P = 0.005) and ABCA1 gene expression increased significantly (fold-change, 1.34; P = 0.05). Gluteal fat adipocyte size (P < 0.0001), macrophage density (P = 0.0067), and TNF-α immunostaining (P = 0.0425) were reduced after RYBG and ABCG1 expression correlated inversely with TNF-α immunostaining (r = -0.71; P = 0.03). Conclusion RYGB enhances HDL functionality in association with a reduction in adipose tissue and systemic inflammation.
- 27 May 2022
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 107 (8) , 2182-2194
Bariatric Surgery-induced High-density Lipoprotein Functionality Enhancement Is Associated With Reduced Inflammation
Background Emerging evidence suggests an association between impaired high-density lipoprotein (HDL) functionality and cardiovascular disease (CVD). HDL is essential for reverse cholesterol transport (RCT) and reduces inflammation and oxidative stress principally via paraoxonase-1 (PON1). RCT depends on HDL’s capacity to accept cholesterol (cholesterol efflux capacity [CEC]) and active transport through ATP-binding cassette (ABC) A1, G1, and scavenger receptor-B1 (SR-B1). We have studied the impact of Roux-en-Y gastric bypass (RYGB) in morbidly obese subjects on RCT and HDL functionality. Methods Biomarkers associated with increased CVD risk including tumour necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hsCRP), myeloperoxidase mass (MPO), PON1 activity, and CEC in vitro were measured in 44 patients before and 6 and 12 months after RYGB. Overweight but otherwise healthy (mean body mass index [BMI] 28 kg/m2) subjects acted as controls. Twelve participants also underwent gluteal subcutaneous adipose tissue biopsies before and 6 months after RYGB for targeted gene expression (ABCA1, ABCG1, SR-B1, TNF-α) and histological analysis (adipocyte size, macrophage density, TNF-α immunostaining). Results Significant (P < 0.05) improvements in BMI, HDL-cholesterol, hsCRP, TNF-α, MPO mass, PON1 activity, and CEC in vitro were observed after RYGB. ABCG1 (fold-change, 2.24; P = 0.005) and ABCA1 gene expression increased significantly (fold-change, 1.34; P = 0.05). Gluteal fat adipocyte size (P < 0.0001), macrophage density (P = 0.0067), and TNF-α immunostaining (P = 0.0425) were reduced after RYBG and ABCG1 expression correlated inversely with TNF-α immunostaining (r = -0.71; P = 0.03). Conclusion RYGB enhances HDL functionality in association with a reduction in adipose tissue and systemic inflammation.
- Open Access
Mathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
Objective: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Design: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year ASCVD risk from 5% to 30% were modelled, using the decrease in risk ratio per mmol/L reduction in LDL cholesterol derived from randomised controlled trials (RCTs) of cholesterol-lowering medication. Data source: Summary statistics from 26 RCTs comparing treatment versus placebo or less versus more effective treatment and 12 RCTs in which statin was compared with a higher dose of the same statin or with a similar statin dose to which an adjunctive cholesterol-lowering drug was added. Setting: The different recommended goals are: (1) LDL cholesterol≤2.6 mmol/L (100 mg/dL); (2) LDL cholesterol≤1.8 mmol/L (70 mg/dL); (3) non-high density lipoprotein (HDL) cholesterol decrease of ≥40%; or (4) LDL cholesterol≤1.8 mmol/L (70 mg/dL) or decreased by ≥50% whichever is lower. Participants: RCT participants. Interventions: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors. Main outcome measures: For each of the recommended therapeutic goals, our primary outcome was the number of events prevented per 100 people treated for 10 years (N 100 ) and the number of needed to treat (NNT) to prevent one event over 10 years. Results: At pretreatment LDL cholesterol 4–5 mmol/L, all four goals provided similar benefit with N 100 1.47–16.45 (NNT 6–68), depending on ASCVD risk and pretreatment LDL cholesterol. With initial LDL cholesterol in the range 2–3 mmol/L, the target of 2.6 mmol/L was the least effective with N 100 between 0 and 2.84 (NNT 35–infinity). The goal of 1.8 mmol/L was little better. However, reductions in non-HDL cholesterol by ≥40% or of LDL cholesterol to 1.8 mmol/L and/or by 50%, whichever is lower, were more effective, delivering N 100 of between 0.9 and 9.33 (NNT 11–111). Percentage decreases in LDL cholesterol or non-HDL cholesterol concentration are more effective targets than absolute change in concentration in people with initial values of 4 mmol/L. The time has probably come for the LDL cholesterol goal of <2.6 mmol/L to be abandoned.
Open AccessMathematical modelling of the most effective goal of cholesterol-lowering treatment in primary prevention
Objective: To compare quantitatively different recommended goals for cholesterol-lowering treatment in the primary prevention of atherosclerotic cardiovascular disease (ASCVD). Design: Outcomes at pretreatment low-density lipoprotein (LDL) cholesterol concentrations from 2 to 5 mmol/L and 10-year ASCVD risk from 5% to 30% were modelled, using the decrease in risk ratio per mmol/L reduction in LDL cholesterol derived from randomised controlled trials (RCTs) of cholesterol-lowering medication. Data source: Summary statistics from 26 RCTs comparing treatment versus placebo or less versus more effective treatment and 12 RCTs in which statin was compared with a higher dose of the same statin or with a similar statin dose to which an adjunctive cholesterol-lowering drug was added. Setting: The different recommended goals are: (1) LDL cholesterol≤2.6 mmol/L (100 mg/dL); (2) LDL cholesterol≤1.8 mmol/L (70 mg/dL); (3) non-high density lipoprotein (HDL) cholesterol decrease of ≥40%; or (4) LDL cholesterol≤1.8 mmol/L (70 mg/dL) or decreased by ≥50% whichever is lower. Participants: RCT participants. Interventions: Statins alone or in combination with ezetimibe or proprotein convertase subtilisin/kexin type 9 inhibitors. Main outcome measures: For each of the recommended therapeutic goals, our primary outcome was the number of events prevented per 100 people treated for 10 years (N 100 ) and the number of needed to treat (NNT) to prevent one event over 10 years. Results: At pretreatment LDL cholesterol 4–5 mmol/L, all four goals provided similar benefit with N 100 1.47–16.45 (NNT 6–68), depending on ASCVD risk and pretreatment LDL cholesterol. With initial LDL cholesterol in the range 2–3 mmol/L, the target of 2.6 mmol/L was the least effective with N 100 between 0 and 2.84 (NNT 35–infinity). The goal of 1.8 mmol/L was little better. However, reductions in non-HDL cholesterol by ≥40% or of LDL cholesterol to 1.8 mmol/L and/or by 50%, whichever is lower, were more effective, delivering N 100 of between 0.9 and 9.33 (NNT 11–111). Percentage decreases in LDL cholesterol or non-HDL cholesterol concentration are more effective targets than absolute change in concentration in people with initial values of 4 mmol/L. The time has probably come for the LDL cholesterol goal of <2.6 mmol/L to be abandoned.
- 19 January 2022
- Published by Elsevier in Atherosclerosis
- Vol. 346, 10-17
Glycated apolipoprotein B decreases after bariatric surgery in people with and without diabetes: A potential contribution to reduction in cardiovascular risk
- 19 January 2022
- Published by Elsevier in Atherosclerosis
- Vol. 346, 10-17
Glycated apolipoprotein B decreases after bariatric surgery in people with and without diabetes: A potential contribution to reduction in cardiovascular risk